Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Gains from Investment Securities (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Gains from Investment Securities for 8 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Dec 2025, up 224.14%, and an annual FY2025 reading of $8.9 million, up 224.14% over the prior year.
  • Gains from Investment Securities was $8.9 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $2.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $35.3 million in Q4 2022 and bottomed at -$35.3 million in Q3 2022.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of -$502000.0 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 7143.33% in 2022, while the deepest fall reached 3845.75% in 2022.
  • Year by year, Gains from Investment Securities stood at $487000.0 in 2021, then skyrocketed by 7143.33% to $35.3 million in 2022, then plummeted by 101.42% to -$502000.0 in 2023, then surged by 645.02% to $2.7 million in 2024, then skyrocketed by 224.14% to $8.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ARCT at $8.9 million in Q4 2025, $2.7 million in Q1 2024, and -$502000.0 in Q1 2023.